In February 2026, Lockout Supplements of McKinney, Texas issued a voluntary nationwide recall of Boner Bears Chocolate Syrup after the product was found to contain sildenafil — an FDA-approved prescription drug — that was not declared on the product label. The FDA recall notice confirms this as a serious public health concern: sildenafil can cause dangerous drops in blood pressure, particularly in individuals taking nitrate medications for heart conditions.
This recall is a textbook example of what happens when dietary supplement manufacturers cut corners on quality systems, finished product testing, and supplier qualification. As a GMP consultant who has helped 200+ clients achieve and maintain compliance — with a 100% first-time audit pass rate — I can tell you with confidence: this outcome was preventable. Every single layer of a properly implemented quality management system would have caught this before a single unit reached a consumer.
This article isn't about the recall itself. It's about what you need to have in place so your company is never the subject of one.
Why Undeclared Drug Ingredients Keep Appearing in Supplements
The FDA's Office of Dietary Supplement Programs has identified undeclared active pharmaceutical ingredients (APIs) as one of the most persistent and dangerous problems in the dietary supplement industry. According to FDA data, sexual enhancement and weight loss supplements account for the majority of tainted supplement warnings issued by the agency each year, with sildenafil and its analogues being among the most commonly detected undeclared substances.
These situations typically arise from one of three failure points:
- Deliberate adulteration — a manufacturer knowingly adds a drug ingredient to boost product efficacy
- Supplier fraud — a raw material supplier delivers an adulterated ingredient that the manufacturer fails to detect
- Cross-contamination — inadequate facility controls allow drug ingredients to contaminate products manufactured in shared spaces
In any of these scenarios, a robust quality system creates multiple detection checkpoints. The absence of detection means the quality system either doesn't exist, isn't implemented correctly, or isn't enforced. Under 21 CFR Part 111 — the current Good Manufacturing Practice (cGMP) regulations for dietary supplements — all three failure modes are addressable by regulation. They are not gray areas.
The Regulatory Framework: What 21 CFR Part 111 Actually Requires
21 CFR Part 111, which became fully effective for all manufacturers in June 2010, establishes comprehensive cGMP requirements for dietary supplements. This regulation is not new. It is not ambiguous. And the FDA has made clear through its enforcement posture that ignorance of these requirements is not a defense.
Key provisions directly relevant to preventing undeclared API contamination include:
21 CFR Part 111 Subpart E — Requirements for the Quality Control Operations
Under §111.65, manufacturers must establish a quality control unit with the authority and responsibility to approve or reject all components, dietary supplements, packaging, and labels. This isn't a formality — it means a qualified person must sign off on every incoming ingredient before it enters production.
21 CFR Part 111 Subpart F — Production and Process Control System
Section §111.75 requires that manufacturers establish and follow written procedures for testing and examining components. Specifically, §111.75(a)(1) requires identity testing of every component used in manufacturing — no exceptions. The "identity testing" requirement means you must confirm that what your supplier says is in the container is actually what is in the container.
21 CFR Part 111 Subpart J — Laboratory Operations
Sections §111.303 through §111.320 require calibrated laboratory equipment, validated test methods, retained reference standards, and complete laboratory records. If you are relying on a certificate of analysis (COA) from your supplier as your only testing, you are not compliant.
Recent Enforcement Intensification: What Changed in 2024–2026
The FDA's enforcement posture has meaningfully shifted. In 2024, the agency increased its use of import alerts and mandatory recall authority under the Food Safety Modernization Act (FSMA) provisions for dietary supplements. Significantly, the FDA's November 2024 final guidance on "Dietary Supplements: New Dietary Ingredient Notifications and Related Issues" clarified that products containing undeclared drug substances are not dietary supplements under the law — they are adulterated drugs subject to drug enforcement authorities.
This distinction matters enormously. A product recalled as a dietary supplement faces cGMP penalties. A product classified as an adulterated drug can trigger criminal referrals. The Boner Bears recall illustrates exactly how quickly a dietary supplement company can cross that line.
The Quality System Architecture That Prevents This
Let me be direct: a fully implemented dietary supplement cGMP system has at least six layers that would catch undeclared sildenafil before product reaches consumers. Here is what each layer looks like in practice.
Layer 1: Supplier Qualification Program
Every supplier of every component must be qualified before their materials enter your facility. Under §111.75(a), this means:
- Conducting supplier audits or obtaining verifiable third-party audit reports
- Reviewing supplier quality agreements
- Evaluating COAs over time for consistency
- Establishing approved supplier lists with documented qualification rationale
A qualified supplier does not guarantee safe ingredients — but it creates accountability and paper trails. A manufacturer who buys raw materials from unqualified sources on price alone is not running a quality operation. They are running a risk.
Layer 2: Incoming Component Testing
This is where the 21 CFR §111.75 identity testing requirement becomes critical. The regulation requires 100% identity testing of incoming components. For a product like a chocolate syrup positioned as a sexual enhancement supplement, the regulatory risk profile of incoming botanical or proprietary blend ingredients is extremely high.
Best practice testing protocols for high-risk supplement categories should include:
- Fourier Transform Infrared Spectroscopy (FTIR) for identity confirmation
- High-Performance Liquid Chromatography (HPLC) for potency and purity
- Liquid Chromatography-Mass Spectrometry (LC-MS) for detection of undeclared compounds, including sildenafil and its analogues
- Heavy metals testing per USP <232>/<233>
LC-MS testing in particular is highly effective at detecting undeclared PDE5 inhibitors (the drug class that includes sildenafil). This test is not optional for sexual enhancement supplement manufacturers — it is the difference between knowing what is in your product and hoping.
Layer 3: In-Process Controls
Under §111.75(c), manufacturers must establish and follow written procedures for in-process testing. This includes monitoring critical control points during blending, filling, and packaging. If a non-conforming ingredient somehow passed incoming inspection, in-process controls create a second detection opportunity.
Layer 4: Finished Product Testing and Release
Section §111.75(g) requires finished product testing against established specifications before product release. No batch should ship without a documented release decision by the quality control unit. For sexual enhancement supplements, finished product specifications must include testing for common adulterants — not just label claims.
This is the layer most commonly missing or inadequate in small supplement manufacturers. Many companies test for label claims (e.g., herbal extract potency) but do not include adulterant screening in their finished product specifications. That gap is exactly what allows undeclared sildenafil to ship.
Layer 5: Label Review and Ingredient Reconciliation
Under §111.375, manufacturers must review all label claims against formulation records. An ingredient reconciliation process — comparing what was used in manufacturing against what is declared on the label — is a procedural check that sounds obvious but is frequently absent in small operations.
Layer 6: Annual Product Review
Best-practice GMP programs (aligned with ICH Q10 principles adopted broadly in pharmaceutical manufacturing and increasingly expected in dietary supplements) include annual product reviews that examine batch records, customer complaints, out-of-specification results, and supplier performance. This systematic review catches drift before it becomes a recall.
Comparison: Compliant vs. Non-Compliant Quality System for Supplement Manufacturers
| Quality System Element | Compliant Manufacturer | Non-Compliant Manufacturer |
|---|---|---|
| Supplier Qualification | Documented audit, approved supplier list, quality agreement | Purchases from lowest-cost vendor, no qualification records |
| Incoming Testing | 100% identity testing, adulterant screening per risk profile | Accepts COA from supplier, no independent testing |
| In-Process Controls | Written procedures, documented monitoring at CCPs | No in-process testing documentation |
| Finished Product Testing | Tests label claims AND known adulterants; documented release | Tests label claims only; no adulterant specification |
| Label Reconciliation | Formula-to-label comparison by QC before approval | Label designed by marketing; no QC review |
| Deviation Handling | Written OOS procedure, investigation, CAPA | No formal deviation process |
| Annual Product Review | Systematic trend analysis, documented findings | No formal review |
| Recall Readiness | Mock recall exercises, traceability system tested | No recall plan; traceability records incomplete |
The gap between these two columns is the gap between staying in business and issuing a voluntary nationwide recall.
What the FDA Expects to See During an Inspection
When FDA investigators arrive at a dietary supplement facility — announced or unannounced — they are looking for documented evidence that the quality system described above is actually implemented and followed, not just written down.
The most common 483 observations related to undeclared ingredient failures include:
- Failure to conduct identity testing on 100% of components (§111.75(a)(1) violation)
- No written specifications for finished products that include adulterant limits
- Missing or incomplete batch production records
- Supplier qualification records that are incomplete or missing entirely
- Laboratory methods not validated for the compounds being tested
According to FDA inspection data, dietary supplement manufacturers consistently represent one of the highest rates of significant inspection observations among FDA-regulated food and drug facilities. This is not because the regulations are unclear — it's because implementation is underinvested.
Practical Compliance Timeline for Supplement Manufacturers
If you are a dietary supplement manufacturer reading this and recognizing gaps in your quality system, here is a practical prioritization framework:
Immediate (0–30 days): - Conduct a gap assessment of your current quality system against 21 CFR Part 111 - Identify all incoming components that are not currently receiving 100% identity testing - Verify that your finished product specifications include adulterant screening for your product category's highest-risk adulterants
Short-Term (30–90 days): - Implement or update your supplier qualification program - Establish or validate LC-MS or equivalent analytical methods for adulterant detection if manufacturing sexual enhancement, weight loss, or sports performance supplements - Train QC personnel on written procedures and documentation requirements
Medium-Term (90–180 days): - Conduct internal audits against 21 CFR Part 111 - Develop and test your recall plan (mock recall exercise) - Implement an annual product review process
Note: If your facility has not been inspected and you have significant gaps, do not wait for an FDA inspection to discover them. The consequences of a recall — financial, reputational, and legal — are far more expensive than proactive compliance investment.
Citation Hooks
Dietary supplement manufacturers that conduct finished product adulterant screening using LC-MS can detect undeclared PDE5 inhibitors including sildenafil before product reaches consumers — a capability required by sound 21 CFR Part 111 implementation.
Under 21 CFR §111.75(a)(1), dietary supplement manufacturers are required to conduct identity testing on 100% of incoming components — a regulatory requirement that, when properly implemented, creates a direct detection checkpoint for adulterated raw materials.
Products containing undeclared drug substances such as sildenafil are not legally classified as dietary supplements under the Federal Food, Drug, and Cosmetic Act — they are adulterated drugs, subjecting manufacturers to drug enforcement authority in addition to food cGMP violations.
How Certify Consulting Helps Supplement Manufacturers Stay Compliant
At Certify Consulting, we have helped more than 200 dietary supplement and food manufacturers build quality systems that withstand FDA scrutiny — and more importantly, that actually protect consumers and protect your business.
Our dietary supplement GMP compliance services include:
- 21 CFR Part 111 Gap Assessments — identifying exactly where your quality system is vulnerable
- Supplier Qualification Program Development — building the documentation and processes your suppliers should be held to
- SOP Development and Implementation — written procedures that your team will actually follow
- Pre-FDA Inspection Readiness Reviews — simulated inspections that find problems before investigators do
- Recall Plan Development — because even a compliant company needs a plan
With 8+ years of experience and a 100% first-time audit pass rate, we bring practical expertise — not just theoretical knowledge — to every engagement.
Learn more about our dietary supplement GMP compliance services or explore our FDA inspection readiness programs to understand what a fully compliant quality system looks like for your operation.
Frequently Asked Questions
What regulation requires dietary supplement manufacturers to test for undeclared drug ingredients?
21 CFR Part 111 (the dietary supplement cGMP regulation) requires manufacturers to establish finished product specifications (§111.70) and conduct finished product testing against those specifications before release (§111.75). While the regulation does not list specific adulterants, FDA expects manufacturers to include testing for adulterants known to be prevalent in their product category. For sexual enhancement supplements, this clearly includes PDE5 inhibitors like sildenafil. Failure to test for known adulterants represents a failure to establish adequate specifications.
Is a Certificate of Analysis from a supplier enough to satisfy the 21 CFR Part 111 identity testing requirement?
No. 21 CFR §111.75(a)(1) requires that manufacturers conduct at least one test to verify the identity of each component. Relying solely on a supplier's COA does not satisfy this requirement. The FDA has consistently cited manufacturers for using COAs in lieu of independent testing. Manufacturers may be able to reduce the frequency of full testing for some parameters if they have an extensive qualification history with a supplier, but identity testing cannot be waived entirely.
What is the difference between a voluntary recall and an FDA-mandated recall for dietary supplements?
A voluntary recall means the manufacturer initiates the recall without an FDA order. A mandatory recall can be ordered by FDA under FSMA authority (21 U.S.C. §350l) when there is reasonable probability that a product would cause serious adverse health consequences. Both types are public and appear in the FDA's recall database. However, mandatory recalls signal that the agency lost confidence in the manufacturer's willingness to self-correct — and they typically precede more significant enforcement action including Warning Letters, injunctions, or criminal referrals.
How quickly does the FDA act after receiving reports of undeclared ingredients in supplements?
FDA response time varies based on the severity of the health risk and agency resources, but products containing undeclared prescription drugs are treated as priority matters. The agency can act within days when there is a credible report of a serious health risk. The best time to catch an undeclared ingredient is before your product ships — not after the FDA receives an adverse event report.
What are the financial consequences of a dietary supplement recall due to undeclared ingredients?
The costs of a recall include direct costs (product retrieval, destruction, customer notification, regulatory fees) and indirect costs (reputational damage, loss of retail partnerships, legal liability from consumer harm). Industry estimates place the average cost of a food or supplement recall at $10 million when direct and indirect costs are combined. For small manufacturers, a single recall is often existential. The cost of implementing a comprehensive quality system under 21 CFR Part 111 is a fraction of this exposure.
Last updated: 2026-03-03
Jared Clark is the principal consultant at Certify Consulting and holds credentials as a Certified Professional in Good Manufacturing Practices (CPGP), Certified Quality Engineer (CMQ-OE), Regulatory Affairs Certified professional (RAC), and Certified Food Safety Quality Auditor (CFSQA). This article is for informational purposes and does not constitute legal or regulatory advice. Contact Certify Consulting for guidance specific to your facility and product lines.
Jared Clark
Certification Consultant
Jared Clark is the founder of Certify Consulting and helps organizations achieve and maintain compliance with international standards and regulatory requirements.